Download now: Gold and Silver Mining Stocks

Biotech of the Year

Regeneron Pharmaceuticals (NASDAQ: REGN) Receives Award

Written by Swagato Chakravorty
Posted December 3, 2012 at 4:03PM

Scrip Intelligence, which programs the yearly Scrip Awards, has named Regeneron Pharmaceuticals (NASDAQ: REGN) as “Biotechnology Company of the Year” at the 8th iteration of the awards this year.

From the Sacramento Bee:

Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron, said, "We are honored to be recognized by Scrip, a leading industry publication. This has indeed been a transforming time for Regeneron, as we went from having one approved drug to three, advanced investigational drugs into Phase 3 trials, and created shareholder value that moved Regeneron into the top ranks of the biotechnology industry."

The award recognizes high achievements in the biotech sector within the year for which it is given. The winners are selected by a panel of 16 members representing leaders in the pharmaceutical industry and related research.

Scrip’s award citation ran:

“Regeneron has been transformed over the past year by the U.S. approval of its first major product. On the back of its highly successful launch, the company expects to become profitable for the first time in 2012.”

Regeneron markets three main products in the U.S.: the EYELEA® (aflibercept) Injection, ZALTRAP® (ziv-zflibercept) Injection meant for IV application, and ARCALYST® (rilonacept) Injection, meant for subcutaneous use.

Regeneron’s focus includes ophthalmology, inflammation, cancer research, and hypercholesterolemia.

Related Articles

Successful Biotech IPOs
Kythera Biopharmaceuticals and Intercept Pharmaceuticals opened trading last week at the high ends of their price ranges...
Warren Buffett Bets on Biotech
Berkshire Hathaway (NYSE: BRK.A) is increasing its stake in DaVita Inc. (NYSE: DVA) against an increasing frequency of Diabetes in the U.S.
Biotech ETFs
In an S&P Capital IQ report, three biotech ETFs took the spotlight...


What is the benefit of the email subscription?
While the Wealth Daily website offers access to the articles and reports, as a newsletter subscriber you will be among the first to receive access to the valuable advice, delivered directly to your inbox daily, and you will have access to deals on our exclusive services.
Who Owns Most of the World's Gold?
4% of the World Controls 12.6% of the Gold
Volkswagen: The Dumbest Car Company on the Planet
Will Volkswagen Expedite the Demise of the Internal Combustion Engine?
Organic Farmland Investing
Marc Faber and the Millionaire Farmer
Marijuana Legalization and the Case for Liberty
The Case for Cannabis Legalization
The World's Biggest Cash Crop